Cargando…

The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients

BACKGROUND: The effect of thiopurine immunomodulators on health-related quality of life (HRQoL) in patients with inflammatory bowel disease (IBD) has been controversial. The aims were to evaluate the HRQoL in patients with IBD treated with thiopurines and assess the short- and long-term impacts of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Bastida, Guillermo, Nos, Pilar, Aguas, Mariam, Beltrán, Belén, Iborra, Marisa, Ortiz, Vicente, Garrigues, Vicente, Estevan, Rafael, Ponce, Julio
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2846867/
https://www.ncbi.nlm.nih.gov/pubmed/20196836
http://dx.doi.org/10.1186/1471-230X-10-26
_version_ 1782179507010011136
author Bastida, Guillermo
Nos, Pilar
Aguas, Mariam
Beltrán, Belén
Iborra, Marisa
Ortiz, Vicente
Garrigues, Vicente
Estevan, Rafael
Ponce, Julio
author_facet Bastida, Guillermo
Nos, Pilar
Aguas, Mariam
Beltrán, Belén
Iborra, Marisa
Ortiz, Vicente
Garrigues, Vicente
Estevan, Rafael
Ponce, Julio
author_sort Bastida, Guillermo
collection PubMed
description BACKGROUND: The effect of thiopurine immunomodulators on health-related quality of life (HRQoL) in patients with inflammatory bowel disease (IBD) has been controversial. The aims were to evaluate the HRQoL in patients with IBD treated with thiopurines and assess the short- and long-term impacts of the treatment on HRQoL. METHODS: Ninety-two consecutive patients who started treatment with thiopurines were prospectively included. Evaluation of HRQoL was performed at months 0, 6, and 12 using two questionnaires, the Short-Form Health Survey (SF-36) and the Inflammatory Bowel Disease Questionnaire (IBDQ). RESULTS: Baseline score of IBDQ was 4,6, range (2,31-6,84), with an impairment of the five dimensions of HRQoL compared with inactive patients. Results obtained in 8 dimensions of SF-36 showed worse HRQoL than Spanish general population. At 6 months patients had a significant improvement in overall IBDQ score -5,8 (1,58 -6,97)- and also in all IBDQ dimensions. All the 8 dimensions of SF-36 obtained a significant improvement. At twelve months score of IBDQ was 6,1, range (2,7-6,98), with improvement in all dimensions compared with baseline and 6 months. SF-36 showed a similar significant improvement in all subscales. CONCLUSIONS: Thiopurine immunomodulators alone or with other treatments have a positive and long lasting impact on HRQoL of IBD patients.
format Text
id pubmed-2846867
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28468672010-03-30 The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients Bastida, Guillermo Nos, Pilar Aguas, Mariam Beltrán, Belén Iborra, Marisa Ortiz, Vicente Garrigues, Vicente Estevan, Rafael Ponce, Julio BMC Gastroenterol Research Article BACKGROUND: The effect of thiopurine immunomodulators on health-related quality of life (HRQoL) in patients with inflammatory bowel disease (IBD) has been controversial. The aims were to evaluate the HRQoL in patients with IBD treated with thiopurines and assess the short- and long-term impacts of the treatment on HRQoL. METHODS: Ninety-two consecutive patients who started treatment with thiopurines were prospectively included. Evaluation of HRQoL was performed at months 0, 6, and 12 using two questionnaires, the Short-Form Health Survey (SF-36) and the Inflammatory Bowel Disease Questionnaire (IBDQ). RESULTS: Baseline score of IBDQ was 4,6, range (2,31-6,84), with an impairment of the five dimensions of HRQoL compared with inactive patients. Results obtained in 8 dimensions of SF-36 showed worse HRQoL than Spanish general population. At 6 months patients had a significant improvement in overall IBDQ score -5,8 (1,58 -6,97)- and also in all IBDQ dimensions. All the 8 dimensions of SF-36 obtained a significant improvement. At twelve months score of IBDQ was 6,1, range (2,7-6,98), with improvement in all dimensions compared with baseline and 6 months. SF-36 showed a similar significant improvement in all subscales. CONCLUSIONS: Thiopurine immunomodulators alone or with other treatments have a positive and long lasting impact on HRQoL of IBD patients. BioMed Central 2010-03-02 /pmc/articles/PMC2846867/ /pubmed/20196836 http://dx.doi.org/10.1186/1471-230X-10-26 Text en Copyright ©2010 Bastida et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Bastida, Guillermo
Nos, Pilar
Aguas, Mariam
Beltrán, Belén
Iborra, Marisa
Ortiz, Vicente
Garrigues, Vicente
Estevan, Rafael
Ponce, Julio
The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients
title The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients
title_full The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients
title_fullStr The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients
title_full_unstemmed The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients
title_short The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients
title_sort effects of thiopurine therapy on health-related quality of life in inflammatory bowel disease patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2846867/
https://www.ncbi.nlm.nih.gov/pubmed/20196836
http://dx.doi.org/10.1186/1471-230X-10-26
work_keys_str_mv AT bastidaguillermo theeffectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients
AT nospilar theeffectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients
AT aguasmariam theeffectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients
AT beltranbelen theeffectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients
AT iborramarisa theeffectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients
AT ortizvicente theeffectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients
AT garriguesvicente theeffectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients
AT estevanrafael theeffectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients
AT poncejulio theeffectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients
AT bastidaguillermo effectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients
AT nospilar effectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients
AT aguasmariam effectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients
AT beltranbelen effectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients
AT iborramarisa effectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients
AT ortizvicente effectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients
AT garriguesvicente effectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients
AT estevanrafael effectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients
AT poncejulio effectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients